Bydureon is a diabetes medicine used together with other diabetes medicines including long-acting insulin to treat adults and children aged 10 years and above with type 2 diabetes whose blood glucose (sugar) levels are not adequately controlled with the other medicines. Bydureon contains the active substance exenatide.
Therapeutic Indication
### Therapeutic indication Bydureon is indicated in adults 18 years and older with type 2 diabetes mellitus to improve glycaemic control in combination with other glucose lowering medicinal products when the therapy in use, together with diet and exercise, does not provide adequate glycaemic control (see section 4.4, 4.5 and 5.1 for available data on different combinations). Bydureon is indicated for treatment of type 2 diabetes mellitus in combination with: - Metformin - Sulphonylurea - Thiazolidinedione - Metformin and sulphonylurea - Metformin and thiazolidinedione in adults who have not achieved adequate glycaemic control on maximally tolerated doses of these oral therapies.
Therapeutic Area (MeSH)
N/AATC Code
A10BJ01
ATC Item
exenatide
Pharmacotherapeutic Group
Drugs used in diabetes
Active Substance (Summary)
INN / Common Names
N/A| Substance | CAS | Monograph |
|---|---|---|
| exenatide | N/A | 艾塞那肽 |
EMA Name
Bydureon
Medicine Name
Bydureon
Aliases
N/ANo risk management plan link.
